Migraine preventive medication reduces resource utilization
- PMID: 12603635
- DOI: 10.1046/j.1526-4610.2003.03040.x
Migraine preventive medication reduces resource utilization
Abstract
Objective: To determine if long-term resource utilization is reduced by adding a preventive medication to a migraine management regimen that already includes acute medication.
Background: In 2000, new evidence-based guidelines for the treatment of migraine were released by the US Headache Consortium and the American Academy of Neurology. Although these guidelines emphasize the role of preventive medication in achieving significant clinical improvement, little yet is known concerning the impact of such management on medical and pharmaceutical resources. Methods.-Resource utilization information in a large claims database was analyzed retrospectively.
Results: Adding a preventive medication to migraine management reduced the use of other migraine medications, as well as visits to physician offices and emergency departments. In addition, both acute and preventive medications were associated with lower utilization of computed tomography and magnetic resonance imaging scans.
Conclusion: Migraine preventive drug therapy is effective in reducing resource consumption when added to therapy consisting only of an acute medication.
Comment in
-
Does migraine preventive medication actually reduce resource utilization?Headache. 2003 Nov-Dec;43(10):1116-8; author reply 1118. doi: 10.1046/j.1526-4610.2003.03217.x. Headache. 2003. PMID: 14629251 No abstract available.
Similar articles
-
Does migraine preventive medication actually reduce resource utilization?Headache. 2003 Nov-Dec;43(10):1116-8; author reply 1118. doi: 10.1046/j.1526-4610.2003.03217.x. Headache. 2003. PMID: 14629251 No abstract available.
-
Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.Clin Ther. 2008 Dec;30(12):2452-60. doi: 10.1016/j.clinthera.2008.12.010. Clin Ther. 2008. PMID: 19167603
-
Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.Arch Intern Med. 1999 Apr 26;159(8):857-63. doi: 10.1001/archinte.159.8.857. Arch Intern Med. 1999. PMID: 10219932
-
Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.Pharmacoeconomics. 2005;23(3):259-74. doi: 10.2165/00019053-200523030-00006. Pharmacoeconomics. 2005. PMID: 15836007 Review.
-
Pharmacoeconomic evidence and considerations for triptan treatment of migraine.Expert Opin Pharmacother. 2002 Mar;3(3):237-48. doi: 10.1517/14656566.3.3.237. Expert Opin Pharmacother. 2002. PMID: 11866674 Review.
Cited by
-
Factors Associated with Direct Health Care Costs Among Patients with Migraine.J Manag Care Spec Pharm. 2017 Nov;23(11):1169-1176. doi: 10.18553/jmcp.2017.23.11.1169. J Manag Care Spec Pharm. 2017. PMID: 29083975 Free PMC article.
-
Efficacy of onabotulinumtoxinA treatment in episodic migraine.Front Neurol. 2025 Jan 6;15:1459767. doi: 10.3389/fneur.2024.1459767. eCollection 2024. Front Neurol. 2025. PMID: 39835150 Free PMC article.
-
Future therapeutic perspectives for tension-type headache.Curr Pain Headache Rep. 2007 Dec;11(6):461-4. doi: 10.1007/s11916-007-0234-0. Curr Pain Headache Rep. 2007. PMID: 18173982 Review.
-
Intravenous caffeine citrate vs. magnesium sulfate for reducing pain in patients with acute migraine headache; a prospective quasi-experimental study.Korean J Pain. 2017 Jul;30(3):176-182. doi: 10.3344/kjp.2017.30.3.176. Epub 2017 Jun 30. Korean J Pain. 2017. PMID: 28757917 Free PMC article.
-
Prophylactic treatment of migraine; the patient's view, a qualitative study.BMC Fam Pract. 2012 Mar 9;13:13. doi: 10.1186/1471-2296-13-13. BMC Fam Pract. 2012. PMID: 22405186 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical